Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Genzyme_Genetics
gptkb:Array_Bio_Pharma |
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:can_be_used_with |
Encorafenib
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:formulation |
oral tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Braftovi
|
| gptkbp:indication |
BRAF V600 E or V600 K mutation-positive melanoma
|
| gptkbp:ingredients |
gptkb:binimetinib
|
| gptkbp:is_used_for |
treatment of melanoma
|
| gptkbp:manufacturer |
gptkb:Array_Bio_Pharma
|
| gptkbp:marketed_as |
gptkb:2018
|